EU Backs Earlier-Line Moves in Prostate and Kidney Cancer
Summary
CHMP backed Talzenna plus enzalutamide for earlier use in metastatic hormone-sensitive prostate cancer and Welireg plus lenvatinib for previously treated advanced renal cell carcinoma. Medscape News Europe
Description from Medscape.
Who is covering this
-
EU Backs Earlier-Line Moves in Prostate and Kidney Cancer
CHMP backed Talzenna plus enzalutamide for earlier use in metastatic hormone-sensitive prostate cancer and Welireg plus lenvatinib for previously treated advanced renal cell carcinoma. Medscape News Europe






Comments
Comments need JavaScript.